Development of broadly protective influenza B vaccines
Abstract Influenza B viruses pose a significant threat to global public health, leading to severe respiratory infections in humans and, in some cases, death. During the last 50 years, influenza B viruses of two antigenically distinct lineages (termed ‘Victoria’ and ‘Yamagata’) have circulated in hum...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-024-01058-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544961544159232 |
|---|---|
| author | Chunyang Gu Lavanya Babujee David Pattinson Shiho Chiba Peter Jester Tadashi Maemura Gabriele Neumann Yoshihiro Kawaoka |
| author_facet | Chunyang Gu Lavanya Babujee David Pattinson Shiho Chiba Peter Jester Tadashi Maemura Gabriele Neumann Yoshihiro Kawaoka |
| author_sort | Chunyang Gu |
| collection | DOAJ |
| description | Abstract Influenza B viruses pose a significant threat to global public health, leading to severe respiratory infections in humans and, in some cases, death. During the last 50 years, influenza B viruses of two antigenically distinct lineages (termed ‘Victoria’ and ‘Yamagata’) have circulated in humans, necessitating two different influenza B vaccine strains. In this study, we devised a novel vaccine strategy involving reciprocal amino acid substitutions at sites where Victoria- and Yamagata-lineage viruses differ, leading to the generation of ‘hybrid’ vaccine viruses with the potential to protect against both lineages. Based on antigenic characterization, we selected two candidates and assessed their protective efficacy in a ferret model. Notably, both recombinant HA proteins conferred enhanced protection against heterologous challenges compared to their respective wild-type antigens. These findings show the potential of our novel strategy to develop cross-lineage protective influenza B virus vaccines. |
| format | Article |
| id | doaj-art-3cab32928c904867a80dbd65d00f588f |
| institution | Kabale University |
| issn | 2059-0105 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj-art-3cab32928c904867a80dbd65d00f588f2025-01-12T12:07:13ZengNature Portfolionpj Vaccines2059-01052025-01-011011910.1038/s41541-024-01058-wDevelopment of broadly protective influenza B vaccinesChunyang Gu0Lavanya Babujee1David Pattinson2Shiho Chiba3Peter Jester4Tadashi Maemura5Gabriele Neumann6Yoshihiro Kawaoka7Department of Pathobiological Sciences, Influenza Research Institute, School of Veterinary Medicine, University of Wisconsin-MadisonDepartment of Pathobiological Sciences, Influenza Research Institute, School of Veterinary Medicine, University of Wisconsin-MadisonDepartment of Pathobiological Sciences, Influenza Research Institute, School of Veterinary Medicine, University of Wisconsin-MadisonDepartment of Pathobiological Sciences, Influenza Research Institute, School of Veterinary Medicine, University of Wisconsin-MadisonDepartment of Pathobiological Sciences, Influenza Research Institute, School of Veterinary Medicine, University of Wisconsin-MadisonDepartment of Pathobiological Sciences, Influenza Research Institute, School of Veterinary Medicine, University of Wisconsin-MadisonDepartment of Pathobiological Sciences, Influenza Research Institute, School of Veterinary Medicine, University of Wisconsin-MadisonDepartment of Pathobiological Sciences, Influenza Research Institute, School of Veterinary Medicine, University of Wisconsin-MadisonAbstract Influenza B viruses pose a significant threat to global public health, leading to severe respiratory infections in humans and, in some cases, death. During the last 50 years, influenza B viruses of two antigenically distinct lineages (termed ‘Victoria’ and ‘Yamagata’) have circulated in humans, necessitating two different influenza B vaccine strains. In this study, we devised a novel vaccine strategy involving reciprocal amino acid substitutions at sites where Victoria- and Yamagata-lineage viruses differ, leading to the generation of ‘hybrid’ vaccine viruses with the potential to protect against both lineages. Based on antigenic characterization, we selected two candidates and assessed their protective efficacy in a ferret model. Notably, both recombinant HA proteins conferred enhanced protection against heterologous challenges compared to their respective wild-type antigens. These findings show the potential of our novel strategy to develop cross-lineage protective influenza B virus vaccines.https://doi.org/10.1038/s41541-024-01058-w |
| spellingShingle | Chunyang Gu Lavanya Babujee David Pattinson Shiho Chiba Peter Jester Tadashi Maemura Gabriele Neumann Yoshihiro Kawaoka Development of broadly protective influenza B vaccines npj Vaccines |
| title | Development of broadly protective influenza B vaccines |
| title_full | Development of broadly protective influenza B vaccines |
| title_fullStr | Development of broadly protective influenza B vaccines |
| title_full_unstemmed | Development of broadly protective influenza B vaccines |
| title_short | Development of broadly protective influenza B vaccines |
| title_sort | development of broadly protective influenza b vaccines |
| url | https://doi.org/10.1038/s41541-024-01058-w |
| work_keys_str_mv | AT chunyanggu developmentofbroadlyprotectiveinfluenzabvaccines AT lavanyababujee developmentofbroadlyprotectiveinfluenzabvaccines AT davidpattinson developmentofbroadlyprotectiveinfluenzabvaccines AT shihochiba developmentofbroadlyprotectiveinfluenzabvaccines AT peterjester developmentofbroadlyprotectiveinfluenzabvaccines AT tadashimaemura developmentofbroadlyprotectiveinfluenzabvaccines AT gabrieleneumann developmentofbroadlyprotectiveinfluenzabvaccines AT yoshihirokawaoka developmentofbroadlyprotectiveinfluenzabvaccines |